News & Updates

Ipilimumab plus nivolumab elicits response in mCRPC

02 Jan 2025 by

Use of dual immune checkpoint inhibitors (ICIs), nivolumab and ipilimumab, exhibits responses in some molecularly selected patients with metastatic castration-resistant prostate cancer (mCRPC), including those with mismatch repair deficiency (dMMR), nonsynonymous tumour mutational burden ≥7.1 muts/Mb (hTMB), a BRCA2 mutation (BRCAm), or biallelic CDK12 inactivation (CDK12i).

Ipilimumab plus nivolumab elicits response in mCRPC

02 Jan 2025

Expanding HPV vaccines to mid-adults: Is it worth the shot?

01 Jan 2025

Vaccination against human papillomavirus (HPV) among adults aged 27–45 years (mid-adults) is less cost-effective and generates a greater number needed to vaccinate (NNV) when compared with vaccination of persons aged 26 years and below, reports a study.

Expanding HPV vaccines to mid-adults: Is it worth the shot?

01 Jan 2025

PALOMA-3: Subcutaneous amivantamab makes the grade in Asians with EGFR+ NSCLC

30 Dec 2024 by

For Asian patients with EGFR-mutated advanced non-small-cell lung cancer (NSCLC), subcutaneous (SC) delivery of amivantamab plus lazertinib does not alter the drug’s pharmacokinetic and efficacy profile compared with the intravenous (IV) approach and is associated with fewer infusion-related reactions, according to a subgroup analysis of the phase III PALOMA-3 trial.

PALOMA-3: Subcutaneous amivantamab makes the grade in Asians with EGFR+ NSCLC

30 Dec 2024

Rezvilutamide + ADT delivers improved outcomes for mHSPC patients regardless of age

27 Dec 2024 by

The combination of rezvilutamide plus androgen-deprivation therapy (ADT) proves to be efficacious and well-tolerated in the treatment of patients with high-volume, metastatic, hormone-sensitive prostate cancer (mHSPC) across all age groups, according to a post hoc analysis of the phase III CHART trial.

Rezvilutamide + ADT delivers improved outcomes for mHSPC patients regardless of age

27 Dec 2024

KEYNOTE-811: Add-on pembrolizumab improves OS in HER2+ gastroesophageal cancer

27 Dec 2024 by

Adding pembrolizumab to trastuzumab and chemotherapy significantly improves overall survival (OS) in patients with advanced unresectable or metastatic HER2+ gastric/gastroesophageal junction (G/GEJ) adenocarcinoma and in those with PD-L1 CPS ≥1, according to the protocol-specified final OS analysis of the KEYNOTE-811 trial presented at ESMO Asia 2024.

KEYNOTE-811: Add-on pembrolizumab improves OS in HER2+ gastroesophageal cancer

27 Dec 2024

Hitting OS endpoint reaffirms frontline daratumumab-VCd as SoC for AL amyloidosis

27 Dec 2024 by

The evidence supporting an upfront daratumumab-containing regimen as the SoC for AL amyloidosis is reaffirmed by the significant OS benefit demonstrated in the final analysis of ANDROMEDA

Hitting OS endpoint reaffirms frontline daratumumab-VCd as SoC for AL amyloidosis

27 Dec 2024

What are the risk factors for MACE, malignancy in rheumatoid arthritis?

25 Dec 2024

Factors such as male sex, older age, and prior X-ray examination are linked to an increased risk of major adverse cardiovascular events (MACE) and malignancies in patients with rheumatoid arthritis, according to a study from Japan.

What are the risk factors for MACE, malignancy in rheumatoid arthritis?

25 Dec 2024

Enzalutamide demonstrates modest activity in granulosa cell ovarian tumours

24 Dec 2024

The use of the antiandrogen enzalutamide in patients with granulosa cell ovarian tumour (GCT) falls short in terms of significant radiological response or clinical benefit, according to a phase II trial.

Enzalutamide demonstrates modest activity in granulosa cell ovarian tumours

24 Dec 2024

Imaging breakthrough holds promise for vascular imaging

23 Dec 2024 by

Researchers from the University College London (UCL) in the UK have developed a high-resolution three-dimensional (3D) photoacoustic scanner based on the Fabry-Perot (FP) ultrasound sensor concept and examined its potential as a tool for clinical vascular imaging.

Imaging breakthrough holds promise for vascular imaging

23 Dec 2024

Novel PD-1 inhibitor shows activity against PD-L1 positive recurrent or metastatic cervical cancer

22 Dec 2024

Enlonstobart, a fully humanized and high-affinity anti-PD-1 immunoglobulin G4 monoclonal antibody, shows therapeutic potential in patients with PD-L1 positive recurrent or metastatic cervical cancer (r/mCC), while having an acceptable safety profile, according to an open-label phase II study.

Novel PD-1 inhibitor shows activity against PD-L1 positive recurrent or metastatic cervical cancer

22 Dec 2024

News & Updates

Filter by Specialty:

Specialty:

Ipilimumab plus nivolumab elicits response in mCRPC

Ipilimumab plus nivolumab elicits response in mCRPC

Expanding HPV vaccines to mid-adults: Is it worth the shot?

Expanding HPV vaccines to mid-adults: Is it worth the shot?

PALOMA-3: Subcutaneous amivantamab makes the grade in Asians with EGFR+ NSCLC

PALOMA-3: Subcutaneous amivantamab makes the grade in Asians with EGFR+ NSCLC

Rezvilutamide + ADT delivers improved outcomes for mHSPC patients regardless of age

Rezvilutamide + ADT delivers improved outcomes for mHSPC patients regardless of age

KEYNOTE-811: Add-on pembrolizumab improves OS in HER2+ gastroesophageal cancer

KEYNOTE-811: Add-on pembrolizumab improves OS in HER2+ gastroesophageal cancer

Hitting OS endpoint reaffirms frontline daratumumab-VCd as SoC for AL amyloidosis

Hitting OS endpoint reaffirms frontline daratumumab-VCd as SoC for AL amyloidosis

What are the risk factors for MACE, malignancy in rheumatoid arthritis?

What are the risk factors for MACE, malignancy in rheumatoid arthritis?

Enzalutamide demonstrates modest activity in granulosa cell ovarian tumours

Enzalutamide demonstrates modest activity in granulosa cell ovarian tumours

Imaging breakthrough holds promise for vascular imaging

Imaging breakthrough holds promise for vascular imaging

Novel PD-1 inhibitor shows activity against PD-L1 positive recurrent or metastatic cervical cancer

Novel PD-1 inhibitor shows activity against PD-L1 positive recurrent or metastatic cervical cancer